Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Viral Immunol ; 36(4): 250-258, 2023 05.
Article in English | MEDLINE | ID: covidwho-2259818

ABSTRACT

Severe respiratory involvement that follows a process of immune dysregulation and intense cytokine production remains to be the most dreaded complication of Coronavirus Disease-2019 (COVID-19) infection. The aim of this study was to analyze T lymphocyte subsets and natural killer (NK) lymphocytes in moderate and severe cases of COVID-19 infection and assess their significance in disease severity and prognosis. Twenty moderate cases and 20 severe cases of COVID-19 were studied and compared regarding blood picture, biochemical markers, T lymphocyte population subsets, and NK lymphocytes, which were determined by flow cytometric analysis. On analyzing the flow cytometric data of T lymphocyte cells and their subsets and NK cells in two groups of COVID-19 infection (one group moderate and the other severe cases), some immature NK lymphocyte relative and absolute counts were higher in the severe patients with worse outcome and death, while some mature NK lymphocyte relative and absolute counts were depressed in both groups. Also, interleukin (IL)-6 was significantly higher in severe cases when compared to moderate cases, and there was a positive significant correlation between immature NK lymphocyte relative and absolute counts and IL-6. There was no statistically significant difference between T lymphocyte subsets (T helper and T cytotoxic) with disease severity or outcome. Some immature NK lymphocyte subsets contribute to the widespread inflammatory response that complicates severe cases of COVID-19; therapeutic approaches directed to enhancing NK maturation or drugs that block NK cell inhibitory receptors have a potential role in controlling COVID-19 induced cytokine storm.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , T-Lymphocyte Subsets , Lymphocyte Subsets , Killer Cells, Natural , Lymphocyte Count , Interleukin-6
2.
Cutis ; 106(6): 318-320, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1225960

ABSTRACT

Varicella-zoster virus infection causes 2 distinct forms of disease: varicella (commonly known as chickenpox) and herpes zoster (HZ)(commonly known as shingles). Primary varicella-zoster virus infection results in the diffuse vesicular rash that is characteristic of chickenpox. Following primary infection, varicella-zoster virus remains dormant in the dorsal root ganglia. This latent phase usually lasts for several decades before reactivation occurs. Varicella-zoster virus reactivation normally presents as HZ in middle-aged adults. A number of cutaneous skin manifestations have appeared in relation to the newly diagnosed coronavirus disease 2019 (COVID-19) pandemic and continue to emerge every day. We report a case of HZ complication in a COVID-19-positive woman who was 27 weeks pregnant.


Subject(s)
COVID-19/complications , Herpes Zoster/diagnosis , Pregnancy Complications, Infectious/virology , Virus Activation , Adult , COVID-19/diagnosis , Female , Herpes Zoster/virology , Herpesvirus 3, Human/isolation & purification , Humans , Pregnancy
3.
J Cosmet Dermatol ; 20(6): 1571-1572, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1148076
4.
Dermatol Ther ; 33(4): e13666, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-343270

ABSTRACT

Various cutaneous manifestations have been observed in patients with COVID-19 infection. Herpes zoster is a viral skin disease caused by varicella zoster that remains dormant in the dorsal root ganglia of cutaneous nerves following a primary chicken pox infection. In this report, we describe two cases COVID infection who first presented with herpes zoster. We are here by suggesting that the clinical presentation of HZ at the time of the current pandemic even in patients giving mild or no suggestive history of upper respiratory symptoms should be considered as an alarming sign for a recent subclinical SARS CoV2 infection.


Subject(s)
Coronavirus Infections/diagnosis , Herpes Zoster/diagnosis , Pneumonia, Viral/diagnosis , Aged , Antiviral Agents/therapeutic use , Betacoronavirus , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coinfection , Diagnosis, Differential , Female , Herpes Zoster/drug therapy , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2 , Virus Latency
SELECTION OF CITATIONS
SEARCH DETAIL